Evidence map›Paper›PMID 42266015›Full record

Trial reportInternational journal of cancer2026

Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial.

Jurek Hille, Sylvie Lorenzen, Claudia Pauligk, Victoria Gensch, Peter Thuss-Patience, Eray Goekkurt, Thomas Ettrich, Florian Lordick, Carsten Bokemeyer, Christian Müller and 8 more

Abstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Jurek HilleDepartment of Oncology, Hematology and Bone Marrow Transplantation With Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID https://orcid.org/0009-0008-9069-2587
Sylvie LorenzenDepartment of Medicine III, TUM University Hospital, Technical University of Munich, Munich, Germany.
Claudia PauligkThe Frankfurt Institute for Clinical Cancer Research IKF GmbH, Frankfurt/Main, Germany.
Victoria GenschDKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany.
Peter Thuss-PatienceDepartment of Hematology, Oncology and Cancer Immunology, Charité-University Medicine Berlin, Berlin, Germany.
Eray GoekkurtUniversity Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Thomas EttrichDepartment of Internal Medicine I, Ulm University Medical Center, Ulm, Germany.ORCID https://orcid.org/0000-0002-7654-2442
Florian LordickDepartment of Oncology, Gastroenterology, Hepatology, and Pulmonology, University Cancer Center Leipzig (UCCL), Leipzig University Medical Center, Leipzig, Germany.
Carsten BokemeyerDepartment of Oncology, Hematology and Bone Marrow Transplantation With Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christian MüllerDepartment of Medical Oncology, Evang. Kliniken Essen-Mitte, Essen, Germany.
Peter ReichardtSarcoma Center Berlin-Brandenburg, Helios Klinikum Berlin-Buch, Berlin, Germany.
Martin SöklerOncology Spital Thun, Thun, Switzerland.
Daniel PinkDepartment of Oncology and Palliative Care, Helios Klinikum Bad Saarow, Bad Saarow, Germany.
Stefan ProbstDepartment of Hematology, Oncology and Palliative Medicine, Community Hospital Bielefeld, Bielefeld, Germany.
Thorsten O GoetzeThe Frankfurt Institute for Clinical Cancer Research IKF GmbH, Frankfurt/Main, Germany.
Salah E Al-BatranThe Frankfurt Institute for Clinical Cancer Research IKF GmbH, Frankfurt/Main, Germany.
Sonja LogesDKFZ-Hector Cancer Institute at the University Medical Center Mannheim, Mannheim, Germany.
Melanie JanningDepartment of Oncology, Hematology and Bone Marrow Transplantation With Section Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Funding

Eily Lilly and CompanyE.W. Kuhlmann-StiftungHector II StiftungMargarete Clemens Stiftung
6 · The paper itself

Abstract

Antiangiogenic treatment with ramucirumab (RAM) is a standard second-line option in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma. However, reliable biomarkers are lacking. The phase II RAMIRIS trial compared RAM plus paclitaxel with RAM plus FOLFIRI (5-fluororuracil, leucovorin and irinotecan) in this setting. We present the exploratory biomarker analysis evaluating placental growth factor (PlGF), carbonic anhydrase IX (CAIX), and tryptase. Plasma samples from 99 patients enrolled in RAMIRIS were collected at predefined timepoints (baseline, Cycle 2 Day 1, and Cycle 4 Day 1). PlGF, CAIX, and tryptase were quantified by ELISA. Associations with progression-free survival (PFS) and overall survival (OS) were analyzed using dichotomized biomarker levels and Cox regression models. PlGF levels increased substantially under treatment, whereas CAIX showed a transient rise, followed by a slight decline, and tryptase remained stable. Elevated PlGF levels at baseline and early-treatment (c2d1) were associated with shorter OS in univariate analysis (baseline HR

Indexed as

AdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorEsophageal NeoplasmsEsophagogastric JunctionPlacenta Growth FactorStomach NeoplasmsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntigens, NeoplasmCarbonic Anhydrase IXFemaleFluorouracilHumansAntibodies, Monoclonal, HumanizedAntigens, NeoplasmBiomarkers, TumorCA9 protein, humanCarbonic Anhydrase IXFluorouracilPaclitaxelPGF protein, humanPlacenta Growth FactorRamucirumabbiomarkergastric cancergastroesophageal cancerplacental growth factorramucirumab

Identifiers

PMID42266015
PMCPMC13432362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.